ChromaDex Corporation (CDXC) 

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

Show less

Over the last 12 months, insiders at ChromaDex Corporation have bought $undefined and sold $undefined worth of ChromaDex Corporation stock.

On average, over the past 5 years, insiders at ChromaDex Corporation have bought $73,149.23B and sold $182,873.08B worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 273 shares for transaction amount of $2,146 was made by Lopez Carlos Luis (SVP, General Counsel) on 2025‑03‑07.